Myriad Applauds the Court of Appeals' Decision to Uphold Gene Patenting
"We strongly support the Court's decision that isolated DNA and cDNA are patent-eligible material as both are new chemical matter with important utilities which can only exist as the product of human ingenuity," said
The Federal Circuit also held that five of the Company's six method claims at issue did not satisfy Section 101. More importantly, with respect to the BRCA1 and BRCA2 genes, Myriad has 237 method claims for BRACAnalysis which were not affected by this ruling and remain in full force and effect providing Myriad with equally strong method of use patent protection.
Myriad is committed to researching and commercializing innovative molecular diagnostics products, such as the BRACAnalysis test, to assess a person's risk of developing disease, guide treatment decisions and help improve patient's quality of life. As such, the Company plans to continue its strong commitment to promoting women's health in the areas of hereditary breast and ovarian cancer, advancing and fostering research on the BRCA genes and providing excellent patient access to its test, including offering financial assistance programs to qualifying individuals.
About BRACAnalysis® Testing
BRACAnalysis is a molecular diagnostic product developed by
Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the statements related to the Company's belief regarding the importance of the
Rebecca ChambersDirector, Investor Relations and Corporate Communications (801) 584-1143 email@example.com
News Provided by Acquire Media